Abstract
Despite considerable momentum in the development of RSV vaccines and therapeutics, there remain substantial barriers to the development and licensing of effective agents, particularly in high-risk populations. The unique immunobiology of RSV and lack of clear protective immunological correlates has held back RSV vaccine development, which, therefore, depends on large and costly clinical trials to demonstrate efficacy. Studies involving the deliberate infection of human volunteers offer an intermediate step between pre-clinical and large-scale studies of natural infection. Human challenge has been used to demonstrate the potential efficacy of vaccines and antivirals while improving our understanding of the protective immunity against RSV infection. Early RSV human infection challenge studies determined the role of routes of administration and size of inoculum on the disease. However, inherent limitations, the use of highly attenuated/laboratory-adapted RSV strains and the continued evolutionary adaptation of RSV limits extrapolation of results to present-day vaccine testing. With advances in technology, it is now possible to perform more detailed investigations of human mucosal immunity against RSV in experimentally infected adults and, more recently, older adults to optimise the design of vaccines and novel therapies. These studies identified defects in RSV-induced humoral and CD8+ T cell immunity that may partly explain susceptibility to recurrent RSV infection. We discuss the insights from human infection challenge models, ethical and logistical considerations, potential benefits, and role in streamlining and accelerating novel antivirals and vaccines against RSV. Finally, we consider how human challenges might be extended to include relevant at-risk populations.
Keywords
- Respiratory
- Virus
- Immunity
- Infection
- RSV
- Human challenge
This is a preview of subscription content, access via your institution.
References
A study of an adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26. RSV. preF) based respiratory syncytial virus (RSV) vaccine in the prevention of lower respiratory tract disease in adults aged 60 years and older—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04908683. Accessed 26 Jan 2022
A study of rilematovir in infants and children and subsequently in neonates hospitalized with acute respiratory tract infection due to respiratory syncytial virus (RSV)—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04583280. Accessed 26 Jan 2022
Ackerson B, Tseng HF, Sy LS et al (2018) Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis 69:197–203. https://doi.org/10.1093/cid/ciy991
Agoti CN, Mwihuri AG, Sande CJ et al (2012) Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J Infect Dis 206:1532–1541. https://doi.org/10.1093/infdis/jis570
Alansari K, Toaimah FH, Almatar DH et al (2019) Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics 143:e20182308. https://doi.org/10.1542/peds.2018-2308
Altamirano-Lagos MJ, Díaz FE, Mansilla MA et al (2019) Current animal models for understanding the pathology caused by the respiratory syncytial virus. Front Microbiol 10:873. https://doi.org/10.3389/fmicb.2019.00873
Andrew MK, Bowles SK, Pawelec G et al (2019) Influenza vaccination in older adults: recent innovations and practical applications. Drugs Aging 36:29–37. https://doi.org/10.1007/s40266-018-0597-4
Ascough S, Paterson S, Chiu C (2018) Induction and subversion of human protective immunity: contrasting influenza and respiratory syncytial virus. Front Immunol 9:323. https://doi.org/10.3389/fimmu.2018.00323
Bagga B, Woods CW, Veldman TH et al (2013) Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther 18:785–791. https://doi.org/10.3851/imp2629
Barr R, Green CA, Sande CJ, Drysdale SB (2019) Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis 6:2049936119865798. https://doi.org/10.1177/2049936119865798
Bem RA, Domachowske JB, Rosenberg HF (2011) Animal models of human respiratory syncytial virus disease. Am J Physiol-Lung Cell Mol Physiol 301:L148–L156. https://doi.org/10.1152/ajplung.00065.2011
Blunck BN, Aideyan L, Ye X et al (2021) A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine 39:1248–1256. https://doi.org/10.1016/j.vaccine.2021.01.045
Bont L, Checchia PA, Fauroux B et al (2016) Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther 5:271–298. https://doi.org/10.1007/s40121-016-0123-0
Branche AR, Falsey AR (2015) Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging 32:261–269. https://doi.org/10.1007/s40266-015-0258-9
Bui DS, Lodge CJ, Burgess JA et al (2018) Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med 6:535–544. https://doi.org/10.1016/S2213-2600(18)30100-0
Ciarlitto C, Vittucci AC, Antilici L et al (2019) Respiratory syncityal virus A and B: three bronchiolitis seasons in a third level hospital in Italy. Ital J Pediatr 45:115. https://doi.org/10.1186/s13052-019-0704-0
Coakley E, Ahmad A, Larson K et al (2019) LB6. EDP-938, a novel RSV N-inhibitor, administered once or twice daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study. Open Forum Infect Dis 6:S995–S995. https://doi.org/10.1093/ofid/ofz415.2489
Cohen S, Tyrrell D, Smith A (1991) Psychological stress in humans and susceptibility to the common cold. N Engl J Med 325:606–612. https://doi.org/10.1056/NEJM199108293250903
Colosia AD, Yang J, Hillson E et al (2017) The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS ONE 12:e0182321–e0182321. https://doi.org/10.1371/journal.pone.0182321
Crank MC, Ruckwardt TJ, Chen M et al (2019) A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365:505. https://doi.org/10.1126/science.aav9033
Cui G, Liu H, Li X, Ming L (2020) Preliminary functional and phylogeographic analyses of the 72 nucleotide duplication region in the emerging human respiratory syncytial virus ON1 strain attachment glycoprotein gene. Biomed Pharmacother 123:109800. https://doi.org/10.1016/j.biopha.2019.109800
Darton TC, Blohmke CJ, Moorthy VS et al (2015) Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis 15:840–851. https://doi.org/10.1016/S1473-3099(15)00068-7
Dayananda P, Ascough S, Gardener Z et al (2020) Safety, tolerability and clinical outcomes of RSV infection challenge in older adult volunteers. In: European congress of clinical microbiology and infectious diseases 2020. Paris
DeVincenzo JP, Wilkinson T, Vaishnaw A et al (2010) Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182:1305–1314. https://doi.org/10.1164/rccm.201002-0221OC
DeVincenzo JP, Whitley RJ, Mackman RL et al (2014) Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371:711–722. https://doi.org/10.1056/NEJMoa1401184
DeVincenzo JP, McClure MW, Symons JA et al (2015) Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373:2048–2058. https://doi.org/10.1056/NEJMoa1413275
DeVincenzo J, Tait D, Efthimiou J et al (2019) Human antiviral efficacy, safety and pharmacokinetics of RV521, an inhibitor of the RSV-F protein: a randomized, placebo-controlled, respiratory syncytial virus challenge study. antimicrob agents chemother AAC.01884-19. https://doi.org/10.1128/AAC.01884-19
DeVincenzo J, Cass L, Murray A et al (2020) Safety and antiviral effects of nebulized PC786 in a respiratory syncytial virus challenge study. J Infect Dis. https://doi.org/10.1093/infdis/jiaa716
Effects of EDP-938 in adult hematopoietic cell transplant recipients who are infected with acute respiratory syncytial virus (RSV) of the upper respiratory tract—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04633187. Accessed 26 Jan 2022
Effects of JNJ-53718678 in adult and adolescent participants who had a hematopoietic stem cell transplantation and who are infected with respiratory syncytial virus (RSV)—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04056611. Accessed 26 Jan 2022
Falsey AR, Walsh EE (1998) Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177:463–466. https://doi.org/10.1086/517376
Falsey AR, Walsh EE (2000) Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13:371–384. https://doi.org/10.1128/cmr.13.3.371-384.2000
Falsey AR, Walsh EE (2005) Respiratory syncytial virus infection in elderly adults. Drugs Aging 22:577–587. https://doi.org/10.2165/00002512-200522070-00004
Falsey AR, Singh HK, Walsh EE (2006) Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 78:1493–1497. https://doi.org/10.1002/jmv.20724
Florin TA, Plint AC, Zorc JJ (2017) Viral bronchiolitis. The Lancet 389:211–224. https://doi.org/10.1016/S0140-6736(16)30951-5
Franklin GM, Grady C (2001) The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 33:1028–1033. https://doi.org/10.1086/322664
Fulton RB, Weiss KA, Pewe LL et al (2013) Aged mice exhibit a severely diminished CD8 T cell response following respiratory syncytial virus infection. J Virol 87:12694–12700. https://doi.org/10.1128/JVI.02282-12
Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J et al (2019) Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection. J Infect Dis 219:1207–1215. https://doi.org/10.1093/infdis/jiy655
Gordon SB, Rylance J, Luck A et al (2017) A framework for Controlled Human Infection Model (CHIM) studies in Malawi: report of a Wellcome trust workshop on CHIM in low income countries held in Blantyre, Malawi. Wellcome Open Res 2:70–70. https://doi.org/10.12688/wellcomeopenres.12256.1
Gottlieb J, Torres F, Haddad T et al (2018) A Phase 2b randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Heart Lung Transplant 37:S155. https://doi.org/10.1016/j.healun.2018.01.375
Goya S, Galiano M, Nauwelaers I et al (2020) Toward unified molecular surveillance of RSV: a proposal for genotype definition. Influenza Other Respir Viruses 14:274–285. https://doi.org/10.1111/irv.12715
Graham BS (2017) Vaccine development for respiratory syncytial virus. Viral Pathog Prev Ther Vaccines 23:107–112. https://doi.org/10.1016/j.coviro.2017.03.012
Guvenel A, Jozwik A, Ascough S et al (2020) Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. J Clin Invest 130:523–538. https://doi.org/10.1172/JCI131696
Habibi MS, Chiu C (2017) Controlled human infection with RSV: the opportunities of experimental challenge. Vaccine 35:489–495. https://doi.org/10.1016/j.vaccine.2016.08.086
Habibi MS, Jozwik A, Makris S et al (2015) Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 191:1040–1049. https://doi.org/10.1164/rccm.201412-2256OC
Habibi MS, Thwaites RS, Chang M et al (2020) Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science 370:eaba9301. https://doi.org/10.1126/science.aba9301
Hall CB (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344:1917–1928. https://doi.org/10.1056/NEJM200106213442507
Hall CB, Douglas RG Jr, Schnabel KC, Geiman JM (1981) Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 33:779–783. https://doi.org/10.1128/IAI.33.3.779-783.1981
Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693–698. https://doi.org/10.1093/infdis/163.4.693
Hanfelt-Goade D, Maimon N, Nimer A et al (2018) A phase 2b, randomized, double-blind, placebo-controlled trial of Presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults. In: C17. New insights in acute pulmonary infections. American Thoracic Society, pp A4457–A4457
Hewitt R, Farne H, Ritchie A et al (2015) The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 10:158–174. https://doi.org/10.1177/1753465815618113
Higgins PG, Barrow GI, Tyrrell DA et al (1990) The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 14:3–10. https://doi.org/10.1016/0166-3542(90)90061-b
Hope T, McMillan J (2004) Challenge studies of human volunteers: ethical issues. J Med Ethics 30:110. https://doi.org/10.1136/jme.2003.004440
Human challenge study to evaluate the efficacy of MV-012-968 vaccine—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04690335. Accessed 26 Jan 2022
Inpatient challenge study of rRSV A/Maryland/001/11, a human respiratory syncytial virus challenge strain, administered to healthy adult volunteers—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03624790. Accessed 26 Jan 2022
Intranasal challenge of healthy adults with respiratory syncytial virus (RSV)—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01475305. Accessed 26 Jan 2022
Jamrozik E, Selgelid MJ (2020) COVID-19 human challenge studies: ethical issues. Lancet Infect Dis 20:e198–e203. https://doi.org/10.1016/S1473-3099(20)30438-2
Jamrozik E, Selgelid MJ (2021) History of human challenge studies. In: Jamrozik E, Selgelid MJ (eds) Human challenge studies in endemic settings: ethical and regulatory issues. Springer International Publishing, Cham, pp 9–23
Janssen announces phase 2b data demonstrating its investigational RSV adult vaccine provided 80% protection against lower respiratory infections in older adults|Johnson & Johnson. In: Content lab US. https://www.jnj.com/janssen-announces-phase-2b-data-demonstrating-its-investigational-rsv-adult-vaccine-provided-80-protection-against-lower-respiratory-infections-in-older-adults. Accessed 24 Jan 2022
Jozwik A, Habibi MS, Paras A et al (2015) RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun 6:10224. https://doi.org/10.1038/ncomms10224
Kingston A, Comas-Herrera A, Jagger C, MODEM project (2018) Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. Lancet Public Health 3:e447–e455. https://doi.org/10.1016/S2468-2667(18)30118-X
Kinnear E, Lambert L, McDonald JU et al (2018) Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol 11:249–256. https://doi.org/10.1038/mi.2017.46
Korsten K, Adriaenssens N, Coenen S et al (2020) Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J 2002688. https://doi.org/10.1183/13993003.02688-2020
Kravetz H, Knight V, Chanock R et al (1961) Respiratory syncytial virus. III. Production of illness and clinical observations in adult volunteers. JAMA 176:657–663
Lambert L, Sagfors AM, Openshaw PJM, Culley FJ (2014) Immunity to RSV in early-life. Front Immunol 5:466–466. https://doi.org/10.3389/fimmu.2014.00466
Lee FE-H, Walsh EE, Falsey AR et al (2004) Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 63:191–196. https://doi.org/10.1016/j.antiviral.2004.04.005
Li IW, Hung IF, To KK et al (2010) The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 137:759–768. https://doi.org/10.1378/chest.09-3072
Loubet P, Lenzi N, Valette M et al (2017) Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect 23:253–259. https://doi.org/10.1016/j.cmi.2016.11.014
Luangrath MA, Schmidt ME, Hartwig SM, Varga SM (2021) Tissue-resident memory T cells in the lungs protect against acute respiratory syncytial virus infection. ImmunoHorizons 5:59. https://doi.org/10.4049/immunohorizons.2000067
Luchsinger V, Piedra PA, Ruiz M et al (2012) Role of neutralizing antibodies in adults with community—acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 54:905–912. https://doi.org/10.1093/cid/cir955
Mallia P, Message SD, Kebadze T et al (2006) An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res 7:116. https://doi.org/10.1186/1465-9921-7-116
Martinón-Torres F, Rusch S, Huntjens D et al (2020) Pharmacokinetics, safety, and antiviral effects of multiple doses of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: a randomized phase 1b study. Clin Infect Dis 71:e594–e603. https://doi.org/10.1093/cid/ciaa283
Mazur NI, Higgins D, Nunes MC et al (2018) The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 18:e295–e311. https://doi.org/10.1016/S1473-3099(18)30292-5
McKay E, Higgins P, Tyrrell D, Pringle C (1988) Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 25:411–421. https://doi.org/10.1002/jmv.1890250405
Midulla F, Nenna R, Scagnolari C et al (2019) How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis. J Infect Dis 219:526–534. https://doi.org/10.1093/infdis/jiy496
Mills VJ, Van Kirk JE, Wright PF et al (1971) Experimental respiratory syncytial virus infection of adults. J Immunol 107:123
Mukherjee M, Stoddart A, Gupta RP et al (2016) The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med 14:113. https://doi.org/10.1186/s12916-016-0657-8
Murphy BR, Prince GA, Walsh EE et al (1986) Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24:197–202. https://doi.org/10.1128/jcm.24.2.197-202.1986
Ohuma EO, Okiro EA, Ochola R et al (2012) The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol 176:794–802. https://doi.org/10.1093/aje/kws257
Okiro EA, White LJ, Ngama M et al (2010) Duration of shedding of respiratory syncytial virus in a community study of Kenyan children. BMC Infect Dis 10:15–15. https://doi.org/10.1186/1471-2334-10-15
Openshaw PJ, Chiu C (2013) Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 3:468–474. https://doi.org/10.1016/j.coviro.2013.05.005
Openshaw PJM, Chiu C, Culley FJ, Johansson C (2017) Protective and harmful immunity to RSV infection. Annu Rev Immunol 35:501–532. https://doi.org/10.1146/annurev-immunol-051116-052206
Panagioti E, Klenerman P, Lee LN et al (2018) Features of effective T cell-inducing vaccines against chronic viral infections. Front Immunol 9:276. https://doi.org/10.3389/fimmu.2018.00276
Pandya MC, Callahan SM, Savchenko KG, Stobart CC (2019) A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathog Basel Switz 8:67. https://doi.org/10.3390/pathogens8020067
Patel K, Kirkpatrick CM, Nieforth KA et al (2018) Respiratory syncytial virus—a dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. J Antimicrob Chemother 74:442–452. https://doi.org/10.1093/jac/dky415
Paul C, Brookes B (2015) The rationalization of unethical research: revisionist accounts of the Tuskegee syphilis study and the New Zealand “Unfortunate experiment.” Am J Public Health 105:e12–e19. https://doi.org/10.2105/AJPH.2015.302720
Pennings JLA, Mariman R, Hodemaekers HM et al (2018) Transcriptomics in lung tissue upon respiratory syncytial virus infection reveals aging as important modulator of immune activation and matrix maintenance. Sci Rep 8:16653. https://doi.org/10.1038/s41598-018-35180-2
Piedra F-A, Mei M, Avadhanula V et al (2017) The interdependencies of viral load, the innate immune response, and clinical outcome in children presenting to the emergency department with respiratory syncytial virus-associated bronchiolitis. PLoS ONE 12:e0172953–e0172953. https://doi.org/10.1371/journal.pone.0172953
Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17:1055. https://doi.org/10.1128/CVI.00131-10
Piedra PA, Jewell AM, Cron SG et al (2003) Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Prot Newborns Matern Immun 21:3479–3482. https://doi.org/10.1016/S0264-410X(03)00355-4
Pollard AJ, Bijker EM (2021) A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21:83–100. https://doi.org/10.1038/s41577-020-00479-7
Pringle CR, Filipiuk AH, Robinson BS et al (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11:473–478. https://doi.org/10.1016/0264-410X(93)90290-E
Rhodin MHJ, McAllister NV, Castillo J et al (2021) EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog 17:e1009428–e1009428. https://doi.org/10.1371/journal.ppat.1009428
RSV Study in Adults 60 to 75 Years of Age—Full Text View—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03919591. Accessed 26 Jan 2022
RSV vaccine and mAb snapshot|PATH. https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/. Accessed 17 May 2021
Ruckwardt TJ, Morabito KM, Phung E et al (2021) Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(21)00098-9
Russell CD, Unger SA, Walton M, Schwarze J (2017) The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev 30:481. https://doi.org/10.1128/CMR.00090-16
Sadoff J, De Paepe E, DeVincenzo J et al (2021) Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a HUMAN CHALLENGE STUdy. J Infect Dis. https://doi.org/10.1093/infdis/jiab003
Safety, efficacy and pharmacokinetics of BTA-C585 in a RSV viral challenge study—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02718937. Accessed 26 Jan 2022
Schmidt ME, Varga SM (2018) The CD8 T cell response to respiratory virus infections. Front Immunol 9:678. https://doi.org/10.3389/fimmu.2018.00678
Shi T, McAllister DA, O’Brien KL et al (2017) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet 390:946–958. https://doi.org/10.1016/S0140-6736(17)30938-8
Shi T, Denouel A, Tietjen AK et al (2020) Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 222:S577–S583. https://doi.org/10.1093/infdis/jiz059
Shirley D-AT, McArthur MA (2011) The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine Auckl NZ 2011:3–13. https://doi.org/10.2147/VDT.S23634
Singanayagam A, Footitt J, Kasdorf BT et al (2019) MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation. bioRxiv 706804. https://doi.org/10.1101/706804
Sitthicharoenchai P, Alnajjar S, Ackermann MR (2020) A model of respiratory syncytial virus (RSV) infection of infants in newborn lambs. Cell Tissue Res 380:313–324. https://doi.org/10.1007/s00441-020-03213-w
Strassburg MA (1982) The global eradication of smallpox. Am J Infect Control 10:53–59. https://doi.org/10.1016/0196-6553(82)90003-7
Study to evaluate the efficacy, immunogenicity, and safety of RSVpreF in adults—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05035212. Accessed 26 Jan 2022
Study of RSVpreF vaccination and RSV challenge in healthy adults—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04785612. Accessed 26 Jan 2022
Study of RV521 in the treatment of adult subjects who have undergone HCT with an URTI with RSV—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04267822. Accessed 26 Jan 2022
Taylor G (2017) Animal models of respiratory syncytial virus infection. Vaccine 35:469–480. https://doi.org/10.1016/j.vaccine.2016.11.054
Trento A, Galiano M, Videla C et al (2003) Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. J Gen Virol 84:3115–3120
Tyrrell D, Cohen S, Schlarb J (1993) Signs and symptoms in common colds. Epidemiol Infect 111:143–156. https://doi.org/10.1017/S0950268800056764
Verwey C, Nunes MC (2020) RSV lower respiratory tract infection and lung health in the first 2 years of life. Lancet Glob Health 8:e1247–e1248. https://doi.org/10.1016/S2214-109X(20)30303-X
Waghmare A, Englund JA (2021) Respiratory viruses. Pediatr Transpl Oncol Infect Dis 148–154:e3. https://doi.org/10.1016/B978-0-323-64198-2.00030-0
Walsh EE, Peterson DR, Falsey AR (2004) Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189:233–238. https://doi.org/10.1086/380907
Watt PJ, Robinson BS, Pringle C, Tyrrell D (1990) Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8:231–236. https://doi.org/10.1016/0264-410X(90)90051-M
Williams K, Bastian AR, Feldman RA et al (2020) Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged ≥60 years. J Infect Dis 222:979–988. https://doi.org/10.1093/infdis/jiaa193
Wright PF, Mills VJ, Chanock RM (1971) Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis 124:505–511. https://doi.org/10.1093/infdis/124.5.505
Yoon JG, Noh JY, Choi WS et al (2020) Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults. Sci Rep 10:12106. https://doi.org/10.1038/s41598-020-69017-8
Zaas AK, Chen M, Varkey J et al (2009) Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6:207–217. https://doi.org/10.1016/j.chom.2009.07.006
Zar HJ, Nduru P, Stadler JAM et al (2020) Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health. Lancet Glob Health 8:e1316–e1325. https://doi.org/10.1016/S2214-109X(20)30251-5
Zens KD, Chen JK, Farber DL (2016) Vaccine-generated lung tissue–resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1. https://doi.org/10.1172/jci.insight.85832
Zhang Y, Wang Y, Zhao J et al (2020) Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China. Influenza Other Respir Viruses 14:483–490. https://doi.org/10.1111/irv.12754
Zhu J, Message SD, Qiu Y et al (2014) Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest 145:1219–1229. https://doi.org/10.1378/chest.13-1567
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Dayananda, P., Chiu, C., Openshaw, P. (2022). Controlled Human Infection Challenge Studies with RSV. In: Current Topics in Microbiology and Immunology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2022_257
Download citation
DOI: https://doi.org/10.1007/82_2022_257
Published:
Publisher Name: Springer, Berlin, Heidelberg